

Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- [Nuvalent, Inc.](#) (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation further characterizing the preclinical intracranial activity of its novel HER2-selective inhibitor, NVL-330, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston.

Details of the poster presentation are as follows:

Title: Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor

Abstract Number: B057

Authors: Yuting Sun^{*1}, Kristin L. Andrews¹, Anupong Tangpeerachaikul¹, Michael J. Walsh¹, Nancy E. Kohl², Joshua C. Horan¹, Henry E. Pelish¹

Session: Poster Session B

Session Date and Time: Friday, October 24, 2025, 12:30-4:00 p.m. ET

Location: Exhibit Hall D

**Presenter, corresponding author; ¹Nuvalent, Inc., Cambridge, MA, USA; ²Kohl Consulting, Wellesley, MA, USA*

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

SOURCE Nuvalent, Inc.

Investor Contact

Chelcie Lister
Nuvalent, Inc.
clister@nuvalent.com

Media Contact

Josie Butler
1AB
josie@1abmedia.com

<https://investors.nuvalent.com/2025-10-13-Nuvalent-to-Present-New-Preclinical-Data-for-HER2-Selective-Inhibitor,-NVL-330.-at-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics>